FCMT
TCRR

Founders Capital Management (Texas)’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Founders Capital Management (Texas)’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-100
Closed -$2K – 335
2021
Q2 		$2K Buy
+100
New +$2.02K ﹤0.01% 294

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Founders Capital Management (Texas)'s TCRR Position: Q3 2021 in Review

Founders Capital Management (Texas) sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q3 2021, closing a stake of 100 shares — an estimated $2K sold.

Founders Capital Management (Texas) first reported a position in TCRR in Q2 2021 and held it in 1 quarter. The position peaked at $2K in Q2 2021. 117 funds tracked by Wall St. Rank hold TCRR as of Q3 2021.

  • Founders Capital Management (Texas) reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Founders Capital Management (Texas) sold 100 TCR2 Therapeutics Inc. Common Stock shares in Q3 2021, an estimated $2K.
  • Founders Capital Management (Texas) first reported a position in TCR2 Therapeutics Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Founders Capital Management (Texas)'s TCR2 Therapeutics Inc. Common Stock position peaked at $2K in Q2 2021.
  • 117 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q3 2021.

Based on Founders Capital Management (Texas)'s 13F filing for Q3 2021, filed 12 Oct 2021.